|Bid||68.50 x 100|
|Ask||69.00 x 200|
|Day's range||68.24 - 68.96|
|52-week range||65.38 - 89.45|
|PE ratio (TTM)||6.90|
|Dividend & yield||2.08 (3.05%)|
|1y target est||N/A|
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Disappointing fourth-quarter sales spurred the company to issue a lower 2017 sales guidance.
Gilead Sciences reports first-quarter results on May 2. Here's what to especially keep your eyes on.